Ex-Hospira chief lands a $91.1M goodbye gift; Diagnostics outfit raises $17.6M;

@FierceBiotech: The 2015 Fierce 15 will be announced in a few weeks. Celebrate the winners with us in October at #BIF15. More | Follow @FierceBiotech

@JohnCFierce: Fibrodysplasia ossificans progressive gets my vote as one of the world's creepiest deadly diseases. Tissue to bone. More | Follow @JohnCFierce

> Pfizer ($PFE) has closed its $15 billion acquisition of Hospira, triggering a $91.1 million golden parachute for outgoing CEO F. Michael Ball. News

> Exosome Diagnostics raised $17.6 million in a second stage of Series B financing, bringing its total round to $44.7 million. The company is working on blood-based tests for lung and prostate cancers. More

> BioTime ($BTX) is plotting to list its shares on Tel Aviv Stock Exchange, tapping "an Israeli market that is becoming a center for biomed and emerging technology companies" while maintaining its NYSE ticker, CEO Michael West said. News

Medical Device News

@FierceMedDev: Focus Diagnostics gets FDA blessing to expand label for herpes test. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: Philips unveils consumer, connected health bid featuring app and 5 devices, including watch. Story | Follow @StacyALawrence

@EmilyWFierce: Report: C.R. Bard downplayed serious problems related to blood-clot device. Article | Follow @EmilyWFierce

> Tornier, Wright merger to close soon after foot and ankle implant divestiture. Report

> Allergan to grab AqueSys for $300M+ to add minimally invasive glaucoma microshunt. Story

> Stryker closing South Carolina surgical equipment manufacturing facility. More

Pharma News

@FiercePharma: Pharma market bets on ASEAN in focus ahead of economic pact. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Last week, Novo announced huge production build-up. This week a warehouse for the raw materials. More from FiercePharmaManutacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Novartis finally gets to roll out inaugural biosim Zarxio. What will payers and docs do? More | Follow @CarlyHFierce

> Undeterred by PTO setbacks, Bass slaps new challenges on Acorda patents. Report

> Ka-Ching: F. Michael Ball cashes out of Hospira with $91.1M. More

> AstraZeneca scores FDA nod for long-term Brilinta use. Story

> Novartis snags EU approval for multiple myeloma med Farydak. Article